Prevalence Of Impaired Glucose Tolerance Research Articles

Prevalence of Impaired Glucose Tolerance in Nonpregnant Polycystic Ovarian Syndrome Patients in a Hospital

Prevalence of Impaired Glucose Tolerance in Nonpregnant Polycystic Ovarian Syndrome Patients in a Hospital

Reprogramming of GLP-1 Response at Prediabetes for the Prevention of Type 2 Diabetes: The Role of Albumin and GLP-1 Receptor Agonists

Prediabetes, a condition characterized by elevated blood sugar levels, poses a significant health risk as it increases the likelihood of developing type 2 diabetes, heart disease, and stroke. Despite its prevalence, early detection and intervention can prevent its progression [1]. Global Prevalence of Impaired Glucose Tolerance (IGT); In 2017, the global prevalence of IGT was estimated at 7.3%, affecting 352.1 million individuals [2].

SAT678 Metabolic Disorders In Thalidomide Embryopathy

Abstract Disclosure: A. Tanabe: None. Thalidomide embryopathy (TE) is a disease that develops in neonates born from women who have taken thalidomide during early pregnancy. Most cases of TE are characterized by developmental abnormalities of the limbs and/or auditory organs. In Japan, thalidomide was marketed as an agent for sleep-induce and digestive ulcers from 1958 to 1962. Up to now, 309 patients have been certified and are supported by the government as drug-induced disease. Currently, many of the victims are in their late 50s, and in addition to congenital disabilities, various health issues such as lifestyle-related diseases can be developed. We investigated their metabolic condition using data of medical health checkup between 2017 and 2019. Sixty-five Japanese cases of TE (33 men and 32 women) were included in this study. The mean age was 56.3±1.5 years in men and 56.1±1.2 years in women. The prevalence of upper limb deformities was 70% in men and 72% in women. The mean body mass index (BMI) was 22.7±2.1 in men and 22.5±4.0 in women. Twelve percent of men and 9% of women had a BMI between 25-30, while 9% of women and no men had a BMI of 30 or greater. Liver dysfunction was seen in 67% of men and 19% of women. The mean low-density lipoprotein cholesterol level was 61±19 mg/dL in men and 69±22 mg/dL in women. The mean high-density lipoprotein (LDL) cholesterol level was 116±29 mg/dL in men and 142±35 mg/dL in women, with 21% of men and 56% of women had LDL level of 140 mg/dL or greater. The mean triglyceride (TG) level was 137±82 mg/dL in men and 121±70 mg/dL in women, with 39% of men and 22% of women had a level of 150 mg/dL or greater. The mean fasting blood glucose level was 114±31 mg/dL in men and 102±17 mg/dL in women. The mean HbA1c level was 5.9±0.9% in men and 5.9±0.4% in women. The prevalence of impaired glucose tolerance was 19% in men and 9% in women. Fatty liver evaluated by ultrasonography or CT scan was 56% in men and 41% in women. The patients with fatty liver showed significantly high BMI, body fat percentage and TGs in men, high alanine aminotransferase and TGs in women, respectively, compared to the patients without fatty liver. There was no significant difference in with or without the upper limb abnormalities in both groups. This is the second report of metabolic disorders in TE, following one from our research group in 2015. Although without obvious overweight, thirty percent of the patients had dyslipidemia and 50% of the patients had the fatty liver. Because there was no association between limb abnormalities and metabolic disorders, other factors could be involved in the development of metabolic disorders. The results of this study provide valuable information for future health management in thalidomide embryopathy. (This study was conducted by a research grant from the National Center for Global Health and Medicine, Japan: 21A1015 and a Grant-in-Aid from the Ministry of Health, Labour, and Welfare, Japan: 20KC2005, 23KC2017). Presentation: Saturday, June 17, 2023

OR20-01 Machine Learning-based Steroid Metabolome Analysis In Women With Polycystic Ovary Syndrome Reveals Three Distinct Androgen Excess Subtypes With Different Metabolic Risk Profiles.

Abstract Disclosure: T.P. Rocha: None. E. Melson: None. R.J. Veen: None. L. Abdi: None. T. McDonnell: None. V. Tandl: None. J. Hawley: None. L. Wittemans: None. A. Anthony: None. L. Gilligan: None. F. Shaheen: None. P. Kempegowda: None. C.D. Gillett: None. L. Cussen: None. C. Missbrenner: None. F. Lajeunesse-Trempe: None. H. Gleeson: None. A. Rees: None. L. Robinson: None. C. Jayasenna: None. H.S. Randeva: None. H.S. Randeva: None. G.K. Dimitriadis: None. L.G. Gomes: None. A. Sitch: None. E. Vradi: Employee; Self; Bayer Schering Pharma. A.E. Taylor: None. M.W. O'Reilly: None. B.M. Obermayer-Pietsch: None. M. Biehl: None. W. Arlt: None. Introduction: Polycystic ovary syndrome affects 10% of women and is associated with an increased risk of type 2 diabetes, hypertension, and fatty liver disease. Androgen excess, a defining feature of PCOS, has been implicated as a driver of metabolic risk. Adrenal-derived 11-oxygenated androgens are a component of PCOS-related androgen excess and are preferentially activated in adipose tissue. Here, we aimed to identify PCOS sub-types with distinct steroid metabolomes and compare their cardiometabolic risk parameters. Methods: We prospectively recruited 488 treatment-naïve women with PCOS fulfilling diagnostic Rotterdam criteria [median age 28 (IQR 24-32) years; BMI 27.5 (22.4-34.6) kg/m2] at eight centres in the UK & Ireland (n=208), Austria (n=242), and Brazil (n=38). Participants underwent a standardised assessment, including insulin sensitivity at baseline (HOMA-IR) and across a 2-h oGTT (Matsuda ISI). We used tandem mass spectrometry to measure 11 androgenic serum steroids, including classic and 11-oxygenated androgens. Results were analysed by unsupervised k-means clustering, followed by a comparison of clinical and metabolic phenotype parameters. Results: Machine learning analysis identified three distinct androgen metabolomes: a cluster with mainly gonadal-derived androgen excess (GAE; testosterone, dihydrotestosterone; 21.5% of women), a cluster with mainly adrenal-derived androgen excess (AAE; 11-oxygenated androgens; 21.7%), and a cluster with comparably mild androgen excess (MAE; 56.8%). Age and BMI were similar between groups. Compared to GAE and MAE, the AAE cluster had the highest rates of hirsutism (76.4% vs 67.6% vs 59.9%) and female pattern hair loss (32.1% vs 14.3% vs 21.7%). The AAE cluster had significantly increased insulin resistance as indicated by higher fasting insulin,120min insulin and HOMA-IR, and lower ISI than GAE and MAE clusters (all p<0.01). The AAE cluster had a 2-3fold higher prevalence of impaired glucose tolerance and newly diagnosed type 2 diabetes. Conclusion: Unsupervised cluster analysis revealed three distinct androgen excess subtypes in PCOS. Women within the adrenal androgen excess cluster had a significantly higher prevalence of insulin resistance, impaired glucose tolerance and type 2 diabetes. These results implicate 11-oxygenated androgens as drivers of metabolic risk in PCOS and provide proof-of-principle for an androgen-based stratification tool to guide preventative and therapeutic strategies in PCOS. Presentation Date: Saturday, June 17, 2023

ИНДЕКСЫ СУРРОГАТНОЙ ОЦЕНКИ ИНСУЛИНОРЕЗИСТЕНТНОСТИ У ДЕТЕЙ И ПОДРОСТКОВ С ОЖИРЕНИЕМ

Obesity is the most common reason for the insulin resistance (IR) though obesity in children is not always associated with IR. The markers based on fasting glucose and/or insulin levels and alternative parameters with conventional lipid-based indexes are used in assessing the IR in clinical practice. The purpose of the research was to assess the relationship between alternative IR surrogate biomarkers as follows: triglycerides (TG) to high-density lipoprotein cholesterol (HDL-C), TG/HDL-C ratio; single-point insulin sensitivity estimator (SPISE) index; triglyceride-glucose index (TyG), with generally accepted indices based on the insulin/glucose ratios, such as HOMA-IR, QUICKI, Caro, in a cohort of obese children and adolescents. Materials and methods used: a single-stage multicenter comparative study was conducted involving 127 patients aged 6 to 17 y/o with simple obesity of varying degrees. The following indices were calculated: HOMA-IR = fasting insulin (mU/ml) x fasting plasma glucose (FPG) (mmol/L) / 22.5; QUICKI = 1/Log (Fasting Insulin, µU/ml) + Log (Fasting Glucose, mg/dl); Caro = fasting plasma glucose (mmol/l) / fasting insulin (μU/ml); TG/HDL-C = TG (mmol/L) / HDL-C (mmol/L); triglyceride-glucose index TyG = Ln [fasting TG (mg/dl) x fasting plasma glucose (mg/dl)/2], where Ln is the logarithm; SPISE = 600 × HDL-C0.185/(TG0.2 x BMI1.338). Results: 75 (59%) boys and 52 (41%) girls were included in the study; the median age was 12.9 [10.4; 14.9] y/o. Pre-pubertal development was recorded in 25 (19.7%), pubertal - in 102 (80.3%). The prevalence of impaired glucose tolerance (IGT) was 5.5%. In children with IGT, the SPISE index was lower than in children with normal glucose tolerance (3.69 [3.49; 4.37] vs. 4.8 [3.99; 5.55], p=0.021) with no statistically significant differences between these groups in other markers. In the IGT subgroup, a high negative correlation was found between SDS BMI and SPISE (R=-0.97). In the general SDS group, BMI correlated with insulin (R=+0.24), TG (R=+0.2), HOMA (R=+0.24), Caro (R=-0.26), TG/HDL-C (R=+0.28) and SPISE (R=-0.65). The SPISE index was lower in girls than in boys (4.94 [3.63; 5.73] vs. 4.07 [3.59; 5.16], p = 0.045). No statistically significant differences were recorded for other gender-related markers. A negative correlation was also found between the obesity degree and SPISE in the subgroups of girls (R=-0.49) and boys (R=-0.70) as well as among pre-pubertal children of both genders (R=-0.61). The maximum correlation between SDS BMI and SPISE was recorded in the subgroup of teenagers of both genders (R=-0.88). In the general group, TyG was weakly correlated with HOMA-IR (R=+0.26) and QUICKI (R=-0.24), while SPISE showed a weak association with all studied insulin indices; no statistically significant correlation between insulin indices and TG/HDL-C was found. In the subgroup of girls, no significant relationships between the evaluated markers were found, in the subgroup of boys, TyG weakly correlated with HOMA-IR (R=+0.29) and QUICKI (R=-0.32). Stronger correlations were recorded in boys between SPISE and all studied insulin indices. In the subgroup of prepubertal patients, a correlation was found between TyG and QUICKI (R=-0.44), SPISE and Caro (R=+0.56), SPISE and HOMA-IR (R=-0.50). The TG/HDL-C ratio did not statistically significantly correlate with traditional IR markers. TyG showed weak correlations with HOMA-IR and QUICKI in the general group and the boys’ subgroup. In the prepubertal period, TyG only weakly correlated with QUICKI and did not show strong associations with insulin-based indices in pubertal children. The SPISE index showed correlations with insulin markers both in the main group and in individual subgroups. Conclusion: the SPISE index can be considered as a relatively simple and accessible method for assessing IR in obese children and adolescents.

Prevalence trends and disease burden of diabetes and prediabetes in Chinese adults of Shanghai.

To estimate secular trends and disease burden of diabetes and prediabetes among Chinese adults. Three population-based surveys were performed among Chinese adults in Shanghai in 2002-2003 (n = 12 302), 2009 (n = 7414), and 2017 (n = 18 960). Diabetes and prediabetes were defined using the 1999 World Health Organization (WHO) criteria. Cochran-Armitage trend test was used to examine the trends in prevalence, awareness, and glycemic control status. Disability adjusted life years (DALYs) were estimated to evaluate the disease burden of diabetes-related complications using the population attribution fraction approach based on published data. The age-adjusted prevalence of diabetes increased during the 15-year period (p for trend <.001) and reached 23.0% (95% CI: 22.1 ~ 24.0%) in men and 15.7% (95% CI: 15.1 ~ 16.4%) among women in 2017. The prevalence of impaired glucose tolerance peaked in 2009, whereas that of impaired fasting glucose increased continuously (p for trend <.001). The awareness of diabetes was found to increase and the glycemic control rates decreased over the three surveys. The estimated DALYs of diabetes complications were found to have increased rapidly due to the increasing prevalence of diabetes and the decreasing glycemic control rates. Prediabetes and diabetes affect a considerable proportion of Chinese adults in Shanghai. Our results highlight the necessary to strengthen the community healthcare system in China to guarantee extensive management of diabetes and prediabetes.

A Prospective Study to Identify the Prevalence of Impaired Glucose Tolerance in Patients With Liver Cirrhosis Using Oral Glucose Tolerance Test.

Introduction Diabetes mellitus (DM) is a global health problem that may affect the prognosis of liver cirrhosis by interfering with the various metabolic functions of the body. Hence it is important to know the glycemic status of the patients with liver cirrhosis to anticipate and treat the complications associated with it, which in turn will help in the prognosis. The conventional methods may underestimate impaired glucose tolerance (IGT). Hence, this study was undertaken to identify IGT prevalent among liver cirrhosis patients using an oral glucose tolerance test (OGTT).The aim of our study was to identify the prevalence of IGT in non-diabetic liver cirrhosis patients using OGTT. Materials and methods This was a prospective cross-sectional study done in the Department of General Medicine at Shri BM Patil Medical College and Hospital, Vijayapura. After obtaining institutional ethical committee approval, a sample size of 85 liver cirrhosis patients between the age of 20-80 years who were not known cases of diabetes mellitus were selected from patients attending inpatient and outpatient departments at our hospital. The period of study was from January 2021 to June 2022. Patients were tested with OGTT, and the results were recorded. Results Our study found that IGT was more common in the age group of 40-49 years. All the patients included were males. We found that alcohol-induced liver cirrhosis patients had the maximum of IGT and DM. Our study observed a prevalence of 36.47% of patients with IGT. Our study in addition to IGT, found that DM was more common in 30-39 years, and 24.71% of patients were diagnosed with diabetes mellitus in the 85 patients included in our study. Conclusion We conclude that performing OGTT to find the prevalence of IGT and DM in liver cirrhosis patients will help in diagnosing DM and IGT, aiding in the improvement of the prognosis of the cirrhosis. The glycemic status of the patient may help in deferring the complications associated with poor glucose control. The incidence of potential complications of DM can be reduced by prompt identification and treatment.

Unmasking a silent killer: Prevalence of diagnosed and undiagnosed Diabetes Mellitus among people living with HIV in rural South Africa.

To document the prevalence of Impaired Glucose Tolerance (IGT) and undiagnosed Diabetes Mellitus (DM) and to identify factors associated with undiagnosed DM in People Living With HIV (PLWH). Cross-sectional study performed at Ndlovu Medical Center, Limpopo, South Africa including PLWH aged ≥18 years. Between August and November 2017, 356 HIV-positive participants were included. Information was collected on socio-demographics, DM symptoms and risk factors for DM. IGT and DM were diagnosed using random plasma glucose and/or HbA1c. Factors associated with undiagnosed DM were assessed by comparing participants with newly diagnosed DM to participants without DM. IGT was diagnosed in 172 (48.3%) participants. Twenty-nine (8.1%) participants met the definition of DM, of whom 17 (58.6%) were newly diagnosed. Compared to participants without DM, participants with DM were on average five years older, were more likely to have a positive family history for DM, were less physically active and had higher systolic blood pressure, body mass index and waist circumference. Factors associated with undiagnosed DM included age ≥45 years (OR=3.59) and physical inactivity (OR=3.17). The prevalence of IGT and DM among PLWH is high and more than half of DM cases were undiagnosed. Regular screening for DM in PLWH is recommended, especially in an aging population with additional cardiovascular disease risk factors. This article is protected by copyright. All rights reserved.

Impaired Glucose Tolerance in Patients with Polycystic Ovarian Syndrome

Background: Polycystic ovary syndrome first described by Stein and Leventhal, is a complex genetic trait of unclear etiology characterized by Oligomenorrhea or anovulation, biochemical or clinical hyperandrogenism and polycystic ovarian morphology on ultrasonography. Women with polycystic ovarian syndrome have an increased risk of developing impaired glucose tolerance and type 2 diabetes mellitus. This study aims to determine the prevalence of impaired glucose tolerance in patients with polycystic ovary syndrome. Study Design: Cross-sectional study Study Duration: This study was conducted in the Department of Endocrinology Ayub Teaching Hospital Abbottabad from 1st Nov 2021 to 30th April 2022. Materials and Methods: All patients with age range 16 to 40 years who were diagnosed with polycystic ovarian syndrome were included in the study. Age, ovarian volume, clinical signs of hyperandrogenism, menstrual abnormalities, serum testosterone, blood glucose at baseline and following 75g of oral glucose load, Body mass index etc. were recorded. Data was analyzed using SPSS-23. Results: Among 139 patients, 35(25.2%) were in the age range 16-25 years while 104(74.8%) were in the age range 26-40 years. Mean age was 28.6(SD±4.2) years. 69(49.6%) patients had BMI&gt; 30 Kg/m2, 60(43.2%) had BMI between 25-29.9 Kg/m2, while only 10(7.2%) patients had their BMI within normal range (18.5-24.9). Mean BMI was 30.7 Kg/m2 (SD±4.4). 47(33.8%) patients had ovarian volume less than 25ml while, 92(66.2%) had ovarian volume greater than 25ml. Mean ovarian volume was 25.5(SD±6.7). 106(76.3%) patients had serum testosterone less than 70ng/dl while, 33(23.7%) had serum testosterone greater than 70ng/dl. Mean serum testosterone was 48.8(SD±26.4). Hirsutism and Acne was observed in 92 (66.2%) and 91(65.5%) patients respectively. 75 (54%) women had positive family history of Diabetes, 56 (40.3%) had family history of polycystic ovary syndrome and 71 (51.1%) patients had past or current history of oral contraceptive pills. Impaired glucose tolerance was found in 52(37.4%) patients. Post stratification results were statistically significant. Conclusions: The prevalence of impaired Glucose tolerance with polycystic ovary syndrome can be as high as 37.4%. Increasing age and Body Mass Index, raise serum testosterone level and increasing ovarian volume are significant predictors for developing impaired glucose tolerance in women with polycystic ovary syndrome. Keywords: Polycystic Ovarian Syndrome, Impaired Glucose Tolerance, Predictive Factors.

Influence of ursodeoxycholic acid on blood glucose, insulin and GLP-1 in rats with liver fibrosis induced by bile duct ligation

BackgroundThe prevalence of impaired glucose tolerance and diabetes is much higher in people with cirrhosis than that in the general population. However, there are inadequate concrete guidelines for the management of diabetes in these patients, particularly in the early stage. Bile aids (BAs) have been found to exert hormone-like functions in the control of lipid and glucose metabolism. We studied the effect of ursodeoxycholic acid (UDCA) on glucose levels in rats with cirrhosis induced by bile duct ligation (BDL).MethodsSD rats were divided into three groups: sham operation (Group A); BDL (Group B), and UDCA plus BDL (Group C). After 4 weeks, oral glucose tolerance tests were performed. Serum biochemical parameters and the levels of glucose, insulin, and glucagon-like peptide 1 (GLP-1) were measured. Histopathology of the liver and islet was observed. The gene expression of cholesterol 7α-hydroylase (CYP7A1), microsomal oxysterol 7a-hydroxylase (CYP7B1) in the liver, and Takeda G-protein-coupled receptor-5 (TGR5) in the intestine was determined by real-time PCR.ResultsCompared with Group A, fasting glucose and 1-h and 2-h postprandial glucose levels increased slightly (all P > 0.05), 2-h postprandial insulin levels increased significantly (P < 0.05), 15 min postprandial GLP-1 levels decreased (P < 0.05) in Group B. Compared with Group B, fasting glucose and 1-h postprandial glucose levels decreased (all P < 0.05), 2-h postprandial insulin levels decreased (P < 0.01), and 15 min postprandial GLP-1 levels increased (P < 0.05) in Group C. After UDCA intervention, liver fibrosis induced by BDL was alleviated, and the islet areas were increased (P < 0.05). Compared with Group A, the mRNA expression of CYP7A1 and CYP7B1 in the liver increased, and the mRNA expression of TGR5 in the intestine decreased in Group B (all P < 0.05). Compared with Group B, the mRNA expression of CYP7A1 and CYP7B1 in the liver decreased, and TGR5 in the intestine increased in Group C (P < 0.05).ConclusionsAfter 4 weeks of BDL, the rats developed liver fibrosis and abnormal glucose metabolism. UDCA administration improved liver fibrosis, increased islet area, decreased glucose levels, inhibited genes in BA synthesis, enhanced TGR5 gene expression in the intestine, and further improved islet function.

Relationship between BMI and risk of impaired glucose tolerance and impaired fasting glucose in Chinese adults: a prospective study

BackgroundCurrent studies in most Western countries have largely focused on body mass index (BMI) as an important risk factor for impaired glucose tolerance (IGT) and impaired fasting glucose (IFG), which have different pathophysiological bases. In people with obesity, the prevalence of IGT is higher and the prevalence of IFG is lower. The prevalence of IGT in the Asian population is higher than that in the white population, and the obesity rate in China is still increasing. However, few cohort studies explore the relationship between BMI and the incidence of IGT and IFG in China. We aimed to explore the relationship between BMI and the risk of IGT and IFG in Chinese adults and analyze the differences between them.MethodsThe baseline data were obtained from the 2010 China Chronic Disease and Risk Factor Surveillance, of which 20 surveillance sites were followed up from 2016 to 2017. Finally, in this study, a total of 5,578 studies were grouped into BMI categories of underweight (BMI < 18.5 kg/m2), normal weight (18.5–23.9 kg/m2), overweight (24.0–27.9 kg/m2), and obesity (≥ 28.0 kg/m2). We used the unconditional logistic regression model to analyze the relationship between BMI and the risk of IGT and IFG.ResultsDuring an average follow-up of 6.4 years, 562 developed IGT and 257 developed IFG. After age, gender, urban and rural areas, physical activity, family history of diabetes, hypertension, abdominal obesity, dyslipidemia, and other factors were adjusted, overweight increased the risk of IGT by 35% [odds ratio (OR) 1.35, 95% confidence interval (CI) 1.08–1.70], and obesity increased the risk of IGT by 77% (OR 1.77, 95% CI 1.27–1.47). After the factors consistent with the above were adjusted, only obesity increased the risk of IFG by 122% (OR 2.22, 95% CI 1.39–3.54).ConclusionsIn China, obesity is an important risk factor for IGT and IFG, and the risk of IGT increases during the overweight stage.

Metabolic Syndrome and Its Association with Nutritional and Cardiometabolic Risk Factors: Prevalence among Apparently Healthy Adults in a Rural Community in Southwestern Nigeria

Aim: The study assessed the prevalence of cardiometabolic risk factors associated with metabolic syndrome among apparently healthy adults in rural settlements.&#x0D; Study Design: Descriptive cross-sectional study.&#x0D; Place and Duration: Ejigbo, a rural settlement in Osun State, Southwestern Nigeria, between September and December 2019.&#x0D; Methodology: 271 apparently healthy individuals were recruited using a multistage sampling technique with the WHO STEPS Instrument questionnaire, level of significance set at P= 0.05.&#x0D; Results: The prevalences of overweight and obesity were 96 (35.4%) and 66 (24.4%) respectively. The prevalence of hypertension among respondents was 83 (30.6%). High plasma levels of Total Cholesterol 64 (23.6%), triglyceride 20 (7.4%), LDL-Cholesterol 28 (10.3%) and very high LDL-Cholesterol 31 (11.5%) were found among the respondents. While 72 (26.6%) of the respondents have a low level of HDL-Cholesterol. The prevalence of impaired glucose tolerance among the respondents was 34 (12.6%) when 45 (16.6%) had diabetic plasma glucose levels and 82 (30.3%) for metabolic syndrome.&#x0D; Conclusion: Cardiometabolic risk factors were very high among rural dwellers, especially people without metabolic syndrome. Therefore, public awareness, about those risk factors, should be intensified. Routine medical check-ups and screening should be encouraged.

Plant-Based Dietary Patterns versus Meat Consumption and Prevalence of Impaired Glucose Intolerance and Diabetes Mellitus: A Cross-Sectional Study in Australian Women.

This study aimed to compare the prevalence of impaired glucose tolerance (IGT) and diabetes mellitus (DM) among Australian women following plant-based diets (PBD) compared to regular meat eaters. A cross sectional analysis of the mid-aged cohort (1946–1951) of the Australian Longitudinal Study on Women’s Health was conducted on completers of Survey 7 in 2013 with complete FFQ data available (n = 9102). Dietary patterns were categorized as PBD (vegan, lacto-ovo vegetarian, pesco-vegetarian, semi-vegetarian) and regular meat eaters. Meat eaters were further categorized into high and low consumption and outcomes included self-reported prevalence of IGT and DM. Participants were identified as regular meat eaters (n = 8937) and PBD (n = 175). Prevalence of IGT was lower in PBD (0–1.2%) compared to regular meat eaters (9.1%). Consolidation of PBD to a single group (vegetarians) indicated a lower prevalence of DM in vegetarians compared to regular meat eaters (3.9% vs. 9.1%). Women consuming meat daily/multiple times per day had significantly higher odds of IGT (OR 1.5, 95%CI 1.1 to 2.1, p = 0.02). Individuals consuming processed meat daily/multiple times per day had significantly higher odds of DM compared to those consuming less than daily (Odds ratio (OR) 1.7, 95% confidence interval (CI) 1.3 to 2.3, p < 0.0001). After adjustment for covariates, statistical significance was lost largely due to the addition of BMI to the model. Prevalence of IGT and DM were lower in women following PBD and higher in high consumers of meat and processed meat. The relationship between meat consumption and IGT/diabetes status appears to be mediated, at least in part, by an increase in body mass index (BMI). Future studies are warranted to investigate the mechanisms and other lifestyle factors underpinning the association between high meat consumption and increased risk of IGT and DM.

A CROSS-SECTIONAL STUDY TO FIND THE PREVALENCE OF IMPAIRED GLUCOSE TOLERANCE IN PULMONARY TUBERCULOSIS PATIENTS

Introduction: Higher prevalence of pulmonary tuberculosis in a diabetic patient is a well-known fact. The inverse relationship i.e. higher prevalence of impaired glucose tolerance in a tuberculous population is also being increasingly realized now and it becomes more relevant due to increased prevalence of DM in general population. Aim/ Objective: To nd the prevalence of abnormal glucose tolerance in pulmonary tuberculosis patients and to correlate the glycaemic parameters with the grades of sputum AFB positivity. Materials &amp; Methods: A hospital based prospective observational comparative study was conducted at a tertiary care hospital. A total of 100 consecutive eligible patients of tuberculosis, were included after taking informed parental consent. Data was analyzed using statistical software SPSS ver. 21. Results: Mean age of the study cases was 42.59 years with 78% males to 22% females. On Oral glucose tolerance test, 56% had normal results while 44% had deranged results. Out of the total 44 cases with deranged results, 13% had IGT and 31% had diabetes. A signicant association was observed between deranged OGTT values and higher sputum grades (p&lt;0.05). Glycemic control as measured by glycated haemoglobin was signicantly associated with grade of sputum positivity. HbA1c levels were 5.98% in cases with “scanty” grade while it was 6.18%, 6.53% and 6.99% in cases with grade +1, +2 and +3 respectively (p&lt;0.05). Conclusion: We observed high prevalence of impaired glucose tolerance and diabetes in tuberculosis patients. Impaired results were signicantly associated with higher degree of sputum positivity. We thus recommend diabetes screening in all TB patients by either HbA1c or OGTT and glucose levels should be measured at least every 2 months after the initiation of anti-tuberculosis treatment.

Cardiovascular complications of Cushings syndrome: Impact on morbidity and mortality.

Cardiovascular complications of Cushings syndrome: Impact on morbidity and mortality.

1194-P: Gender Differences in Incidence of Prediabetes and Diabetes in South Asians

Background: Among South Asians, women have higher prevalence of diabetes than men, but few studies have examined gender differences in incidence. Methods: We analyzed data from 2714 adults aged ≥20 years, enrolled in the Chennai site of prospective Cardiometabolic risk reduction in South Asia (CARRS) study. We defined normal glucose tolerance (NGT) , isolated impaired fasting glucose (iIFG) , impaired glucose tolerance (IGT) , and diabetes based on ADA criteria. We estimated incidence densities for: NGT (n=2205) to iIFG and iIFG (n=641) to diabetes; NGT (n=2205) to IGT; and IGT (n=341) to diabetes. Results: Prevalence of iIFG was higher in women (20.5% vs. 11.8%) , while prevalence of IGT was lower (6.6% vs. 8.5%) than in men. During median 2.6 y (IQR: 0.7, 5.8) of follow-up, 316 individuals progressed from NGT to iIFG, 239 from NGT to IGT, 155 from iIFG to diabetes, and 135 from IGT to diabetes. Overall, incidence (95% CI) of NGT to iIFG was higher than incidence of NGT to IGT (36.3 [32.5, 40.5] vs. 27.4 [24.1, 31.1] per 1,000 person-years [PYR], respectively) . However, the incidence of iIFG to diabetes was lower than incidence of IGT to diabetes (47.3 [40.4, 55.4] vs. 77.1 [65.1, 91.3] per 1,000 PYR, respectively) . Compared with men, women had higher conversion from NGT to iIFG (42.1 [36.9, 48] vs. 27.7 [22.7, 33.8]) , but lower incidence of NGT to IGT, 22.9 (19.2, 27.4) vs. 34.2 (28.5, 40.9) . Women had higher conversation both from iIFG to diabetes [49.0 (40.8,58.8) vs. 43.1 (31.6,58.7) ] and IGT to diabetes (87.7 [70.5,109.0] vs. 65.3 [50.0,85.2]) . In Cox models adjusting for age, BMI and family history of diabetes, women were 1.41 times (95% CI: 1.07,1.84) likely to convert from NGT to iIFG compared to men, but, men are 1.76 (1.33, 2.34) times at risk from NGT to IGT. There was no gender difference for conversion from iIFG or IGT to diabetes. Conclusion: Prevalence and incidence of iIFG is higher in South Asian women than men, while prevalence and incidence of IGT is higher in men. Conversion from iIFG or IGT to diabetes is similar among genders. Disclosure K.Narayan: n/a. H.H.Chang: None. N.Tandon: None. V.Mohan: None. D.Kondal: None. L.R.Staimez: None. R.Anjana: None. U.Gujral: None. M.Deepa: None. S.A.Patel: Research Support; Johnson &amp; Johnson. M.K.Ali: Advisory Panel; Bayer AG, Research Support; Merck &amp; Co., Inc. D.Prabhakaran: None. Funding The National Heart, Lung, and Blood Institute (NHLBI) , National Institutes of Health (HHSN268200900026C)

Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden

ObjectiveTo assess the effect of adding an oral glucose tolerance test (OGTT) to fasting plasma glucose (FPG) in terms of detection of type 2 diabetes (T2D) and impaired glucose tolerance...

High Albumin Level Is Associated With Regression of Glucose Metabolism Disorders Upon Resolution of Acute Liver Inflammation in Hepatitis B-Related Cirrhosis.

Background and AimTo investigate the short-term dynamic changes and the factors associated with regression of glucose metabolism disorders in patients with hepatitis flare of chronic hepatitis B virus (HBV) infection.MethodsIn this study, 118 patients with severe hepatitis flare of chronic HBV infection were prospectively studied. Oral glucose tolerance test was performed on admission and during follow-up to evaluate dynamic changes in glucose metabolism disorders. The factors associated with regression of glucose metabolism disorders were identified using univariate and multivariate logistic regression analyses.ResultsThe prevalence of diabetes was significantly higher in 70 (47.1%) patients with liver cirrhosis than that in 48 (16.8%) patients without liver cirrhosis. The prevalence of impaired glucose tolerance in patients with liver cirrhosis (35.7%) was significantly lower than that in patients without liver cirrhosis (47.8%). After a follow-up of 20.0 ± 18.7 days, 28 of 31 (90.3%) patients without liver cirrhosis experienced regression of glucose metabolism disorders. Additionally, 30 (54.5%) patients with liver cirrhosis experienced regression of glucose metabolism disorders after 42.0 ± 36.2 days. In patients with liver cirrhosis, those with regression of glucose metabolism disorders had significantly higher levels of homeostasis model assessment-β-cell function, albumin (ALB), and a significantly lower level of fibrosis-4 score. ALB was identified as an independent factor associated with the regression of glucose metabolism disorders in patients with liver cirrhosis.ConclusionSevere acute liver inflammation aggravates glucose metabolism disorders in patients with hepatitis B-related liver cirrhosis and high ALB level is associated with regression of glucose metabolism disorders upon resolution of acute liver inflammation.

Abstract P4-11-33: Continuous glucose monitoring and hyperglycemia during chemotherapy for early-stage breast cancer

Abstract Background: There are a growing number of breast cancer (BC) survivors who are at risk for short and long-term treatment-related toxicities. BC survivors may be at higher risk of developing diabetes mellitus (DM), and chemotherapy may potentiate this risk due to concurrent corticosteroid use. DM is associated with both short and long-term treatment toxicities and worse BC outcomes. The prevalence of hyperglycemia (HG) during chemotherapy for early-stage BC (ESBC), and the association between HG during chemotherapy and treatment-related toxicities is unknown. Methods: We are conducting a single-arm pilot study to evaluate the prevalence of hyperglycemia among patients with ESBC during chemotherapy (NCT04473378). Patients are eligible if ≥18 years old, initiating chemotherapy with corticosteroid use, not receiving systemic steroids except as supportive care for chemotherapy, and known DM is allowed if patients are not treated with insulin. Within 7 days of chemotherapy initiation, the Freestyle Libre Pro (Abbott Diabetes Care) continuous glucose monitoring system is applied to the posterior arm of each participant. Patches are reapplied every 2-3 weeks and worn continuously until chemotherapy completion (duration per regimen). The Freestyle Libre Pro monitors interstitial glucose every 15 minutes via subcutaneous sensor filaments adhered to the skin without a finger prick. Data is downloaded using a wireless scan of the sensor by a reader. The primary endpoints are: 1) the prevalence of HG, defined as the number of participants who have ≥1 glucose value (fasting or non-fasting) of ≥140 mg/dL at any point from chemotherapy initiation to completion; 2) Among participants who develop HG, the proportion of time in which they have HG, measured as the number of hyperglycemic values (glucose value of ≥140 mg/dL) divided by the total number of glucose values recorded in an individual for the duration of chemotherapy. Secondary endpoints include the prevalence of impaired glucose tolerance (hemoglobin A1c [HgbA1c] ≥5.7%) prior to chemotherapy initiation in patients without a history of DM, and changes in glucose biomarkers (HgbA1c, fructosamine, and serum creatinine) during treatment. Results: Between December 2020 and April 2021, 7 patients were enrolled, with evaluable data for 5 patients. At baseline median age was 60 (range, 37-74) and median BMI was 33.0 (range, 24.6-41.6). Chemotherapy regimens were: docetaxel/cyclophosphamide (40%); docetaxel/cyclophosphamide/trastuzumab/pertuzumab (20%); weekly paclitaxel (20%); and paclitaxel followed by doxorubicin/cyclophosphamide (20%). All patients (100%) developed hyperglycemia. Of 18,768 sensor readings (281,265 minutes) the proportion of time participants were hyperglycemic (≥140 mg/dL) during the period of adjuvant/neoadjuvant chemotherapy was 22.1%, and the mean time from first corticosteroid administration to first hyperglycemic episode was 7.6 hours. Of three patients with no history of DM (including one patient with glucose intolerance), the proportion of time spent hyperglycemic (≥140 mg/dL) was 9.9% (range, 1.7-13.8%), and the mean daily glucose was 106.7 mg/dL (SD 10.3). Of the two patients with DM, the proportion of time spent hyperglycemic was 70.2% (range, 67.2-79.5%) and the mean daily glucose was 171.7 mg/dL (SD 3.1). Changes in glucose biomarkers will be presented with the full cohort. Conclusion: Hperglycemia during chemotherapy occurred in 100% of the cohort, including those without a history of DM or glucose intolerance. It is currently unknown if HG during chemotherapy is a modifiable risk factor for short and long-term BC treatment toxicities including neuropathy. Understanding glucose trends in this setting will help determine a successful intervention for HG during chemotherapy which may reduce short and long-term treatment toxicities. Citation Format: Melissa K Accordino, John H Spivack, Sophie Ulene, Erin Honan, Meghna S Trivedi, Katherine D Crew, Erik Harden, Cynthia Law, Dawn L Hershman. Continuous glucose monitoring and hyperglycemia during chemotherapy for early-stage breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-11-33.

Prevalence of Impaired Oral Glucose Tolerance in Patients with Polycystic Ovarian Syndrome

Objectives: To find the prevalence of PCOS in patients with menstrual irregularities and then to find the prevalence of impaired glucose tolerance among patients with PCOS. Study design: Descriptive cross sectional Place and Duration of Study: Department of Obstetrics and Gynecology, District Headquarter Hospital, Gujranwala from 1st November 2017 to 2nd May 2018. Methodology: Two hundred and twenty threepatients with menstrual irregularities were included In the study. Rotterdam classification criteria were used for proper identification of polycystic ovarian syndrome facilitated by clinical investigation. These patients were called for the oral GTT as explained in operational definitions. All blood samples were sent to our hospital laboratory. Results: Mean age of women was 32.54±7.54 years. Among women, 120 (53.8%) had family history of diabetes. Impaired glucose tolerance was confirmed in 55(24.7%) patients. Women who were diagnosed with PCOS among them impaired glucose tolerance was confirmed in 20(18.2%) patients. Conclusion: Glucose tolerance frequency was not significantly higher. However elderly and obese women had higher frequency of impaired glucose tolerance. Key words: PCOS, Menstrual irregularities, Impaired, Glucose, Tolerance